Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · IEX Real-Time Price · USD
22.74
-0.73 (-3.11%)
At close: Apr 24, 2024, 4:00 PM
22.81
+0.07 (0.31%)
After-hours: Apr 24, 2024, 7:59 PM EDT
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Beam Therapeutics stock have an average target of 43.1, with a low estimate of 30 and a high estimate of 57. The average target predicts an increase of 89.53% from the current stock price of 22.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BEAM stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 3 | 3 | 3 | 4 |
| Hold | 4 | 6 | 6 | 6 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 11 | 10 | 10 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $57 | Buy | Reiterates | $57 | +150.66% | Apr 23, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $57 | Buy | Maintains | $57 | +150.66% | Mar 27, 2024 |
| Barclays | Barclays | Hold Maintains $26 → $42 | Hold | Maintains | $26 → $42 | +84.70% | Feb 28, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $27 → $35 | Hold | Maintains | $27 → $35 | +53.91% | Feb 28, 2024 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $38 → $40 | Hold → Buy | Upgrades | $38 → $40 | +75.90% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
64.68M
from 377.71M
Decreased by -82.87%
Revenue Next Year
65.58M
from 64.68M
Increased by 1.39%
EPS This Year
-5.48
from -1.72
EPS Next Year
-5.17
from -5.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.0M | 115.5M | 87.4M | 349.7M | 729.3M |
| Avg | 64.7M | 65.6M | 48.8M | 206.7M | 580.2M |
| Low | n/a | n/a | n/a | 95.2M | 484.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -72.2% | 78.6% | 33.3% | 616.0% | 252.9% |
| Avg | -82.9% | 1.4% | -25.5% | 323.1% | 180.8% |
| Low | - | - | - | 95.0% | 134.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.74 | -3.64 | -5.42 | -3.77 | -0.86 |
| Avg | -5.48 | -5.17 | -5.57 | -4.01 | -1.66 |
| Low | -8.67 | -5.73 | -6.17 | -4.71 | -2.51 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.